$BMSN Recent Headlines 10-K: BIO-MATRIX SCIENTIF

$BMSN Recent Headlines

10-K: BIO-MATRIX SCIENTIFIC GROUP, INC. 2:51 p.m. Jan. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-Q: BIO-MATRIX SCIENTIFIC GROUP, INC. 11:52 a.m. Aug. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 1:00 p.m. July 31, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 10:02 a.m. June 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 9:49 a.m. June 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 9:42 a.m. June 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: BIO-MATRIX SCIENTIFIC GROUP, INC. 12:07 p.m. May 17, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: BIO-MATRIX SCIENTIFIC GROUP, INC. 12:01 p.m. March 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: BIO-MATRIX SCIENTIFIC GROUP, INC. 3:26 p.m. March 6, 2013 - Edgar Online - (EDG = 10Q, 10K)

Regen BioPharma Announces HemaXellerate I(TM) Efficacy Data in Animal Model of Aplastic Anemia 9:35 a.m. Dec. 11, 2013 - Marketwire
Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I 10:36 a.m. Oct. 31, 2013 - Marketwire
New In-Depth Stock Reports on BMSN, CERP, NAMG and NVIV 12:03 a.m. Oct. 25, 2013 - ACCESSWIRE
Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders 2:12 p.m. Oct. 9, 2013 - Marketwire
Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I Covering Aplastic Anemia 7:01 a.m. Sept. 26, 2013 - Marketwire
Bio-Matrix Scientific Group's Subsidiary, Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product 7:31 a.m. Sept. 25, 2013 - Marketwire
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board 9:07 a.m. Sept. 17, 2013 - Marketwire
Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program 12:49 p.m. Aug. 16, 2013 - Marketwire
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma 8:48 a.m. Aug. 8, 2013 - Marketwire
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program 1:37 p.m. July 31, 2013 - Marketwire
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program 7:30 a.m. June 7, 2013 - Marketwire
Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer 7:31 a.m. May 6, 2013 - Marketwire
Bio Matrix Scientific Group & IceWEB Inc Trend Review: (OTCQB: BMSN), (OTCQB: IWEB) 12:26 p.m. April 5, 2013 - ACCESSWIRE-TNW
Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development 3:10 p.m. April 4, 2013 - Marketwire
Regen BioPharma Receives IND # From FDA for HemaXellerate 8:58 a.m. March 18, 2013 - Marketwire
Small-Cap Specialists Issues Three New Research Reports (PINKSHEETS: BMSN), (PINKSHEETS: GBHL) and (OTCQB: NNAN) 9:58 a.m. Feb. 28, 2013 - Marketwire
Bio-Matrix' Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing Technology for Use in Treating Breast Cancer 10:14 a.m. Feb. 26, 2013 - Marketwire
Cannabis Science & Bio-Matrix Scientific Group in the News: (OTCQB: CBIS), (OTC Pink: BMSN) 12:50 a.m. Feb. 18, 2013 - ACCESSWIRE-TNW
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia 10:36 a.m. Feb. 5, 2013 - Marketwire
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product 2:54 p.m. Jan. 24, 2013 - Marketwire